These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2958851)

  • 21. Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist.
    Rolandi E; Franceschini R; Giberti C; Brancadoro T; Martorana G; Barreca T
    Horm Res; 1988; 30(1):22-5. PubMed ID: 2975631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
    Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV
    Prostate; 1989; 14(4):291-300. PubMed ID: 2526325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. German Leuprorelin Study Group.
    Bischoff W
    J Int Med Res; 1990; 18 Suppl 1():103-13. PubMed ID: 2108882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer.
    Navratil H
    J Int Med Res; 1990; 18 Suppl 1():69-73. PubMed ID: 2108887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction and maintenance of castration by an LHRH analogue: D-Trp6 LHRH or decapeptyl.
    Fretin J; Demerle F; Jardin A
    Prog Clin Biol Res; 1987; 243A():245-7. PubMed ID: 2958855
    [No Abstract]   [Full Text] [Related]  

  • 26. Decapeptyl in the treatment of metastatic prostatic cancer. Comparative study with pulpectomy.
    Botto H; Richard F; Mathieu F; Camey M
    Prog Clin Biol Res; 1987; 243A():199-206. PubMed ID: 2958850
    [No Abstract]   [Full Text] [Related]  

  • 27. The first clinical use of depot buserelin for advanced prostatic carcinoma.
    Waxman JH; Sandow J; Man A; Barnett MJ; Hendry WF; Besser GM; Oliver RT; Magill PJ
    Cancer Chemother Pharmacol; 1986; 18(2):174-5. PubMed ID: 3098445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of carcinoma of the prostate with analogs of LHRH].
    Rubio Herrera MA; Calle Fernández JR
    Rev Clin Esp; 1986 Nov; 179(8):407-11. PubMed ID: 2951782
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacokinetics of D-Trp6 LHRH in man: sustained release polymer microsphere study (I.M. route).
    Drieu K; Devissaguet JP; Duboistesselin R; Dray F; Ezan E
    Prog Clin Biol Res; 1987; 243A():435-7. PubMed ID: 2958864
    [No Abstract]   [Full Text] [Related]  

  • 30. Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients.
    Wenderoth UK; Happ J; Krause U; Adenauer H; Jacobi GH
    Eur Urol; 1982; 8(6):343-7. PubMed ID: 6814918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH; Hendry WF; Whitfield HN; Oliver RT
    Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical development of nafarelin acetate. Phase I and phase II studies.
    Hoffman PG; Henzl MR; Chaplin MD; Nerenberg CA
    J Androl; 1987; 8(1):S17-22. PubMed ID: 2951357
    [No Abstract]   [Full Text] [Related]  

  • 33. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
    Waxman J
    Prog Clin Biol Res; 1989; 303():61-8. PubMed ID: 2528741
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group.
    Sharifi R; Soloway M
    J Urol; 1990 Jan; 143(1):68-71. PubMed ID: 2104638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
    J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
    Williams G; Kerle D; Griffin S; Dunlop H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Dec; 289(6458):1580-1. PubMed ID: 6239674
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue.
    Smith JA
    Prog Clin Biol Res; 1985; 185A():279-85. PubMed ID: 3929267
    [No Abstract]   [Full Text] [Related]  

  • 39. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.
    Falkson CI; Falkson G; Falkson HC
    Ann Oncol; 1991 Apr; 2(4):303-4. PubMed ID: 1907843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A
    Prostate; 1987; 11(3):243-55. PubMed ID: 2960957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.